{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:43:03Z","timestamp":1648622583910},"reference-count":21,"publisher":"Akademiai Kiado Zrt.","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155\/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155\/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155\/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy. Orv. Hetil., 2014, 155(36), 1437\u20131444.<\/jats:p>","DOI":"10.1556\/oh.2014.29984","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T01:01:04Z","timestamp":1409533264000},"page":"1437-1444","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for cancer in patients with myositis. Clinical, immunological characteristics and the role of the anti-p155\/140 antibody"],"prefix":"10.1556","volume":"155","author":[{"given":"Zsuzsanna","family":"Szankai","sequence":"first","affiliation":[{"name":"Debreceni Egyetem, Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Belgy\u00f3gy\u00e1szati Int\u00e9zet, Klinikai Immunol\u00f3giai Tansz\u00e9k Debrecen M\u00f3ricz Zsigmond krt. 22. 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Nagy-Vincze","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Belgy\u00f3gy\u00e1szati Int\u00e9zet, Klinikai Immunol\u00f3giai Tansz\u00e9k Debrecen M\u00f3ricz Zsigmond krt. 22. 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levente","family":"Bodoki","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Belgy\u00f3gy\u00e1szati Int\u00e9zet, Klinikai Immunol\u00f3giai Tansz\u00e9k Debrecen M\u00f3ricz Zsigmond krt. 22. 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Jakab","sequence":"additional","affiliation":[{"name":"Medical University of Vienna Department of Biomedical Imaging and Image-guided Therapy Vienna Ausztria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Betteridge","sequence":"additional","affiliation":[{"name":"University of Bath Royal National Hospital for Rheumatic Diseases Bath Egyes\u00fclt Kir\u00e1lys\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dank\u00f3","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, Klinikai K\u00f6zpont, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Belgy\u00f3gy\u00e1szati Int\u00e9zet, Klinikai Immunol\u00f3giai Tansz\u00e9k Debrecen M\u00f3ricz Zsigmond krt. 22. 4032"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"1","unstructured":"<i>Dank\u00f3, K., Ponyi, A., Constantin, T.:<\/i> New data about inflammatory myopathies. [\u00dajabb adatok a gyullad\u00e1sos izombetegs\u00e9gekr\u0151l.] Lege Artis Med., 2006, <i>16<\/i>(5), 445\u2013452. [Hungarian]"},{"key":"2","doi-asserted-by":"crossref","unstructured":"<i>Ponyi, A., Constantin, T., Garami, M., et al.:<\/i> Cancer-associated myositis: clinical features and prognostic signs. Ann. N. Y. Acad. Sci., 2005, <i>1051,<\/i> 64\u201371.","DOI":"10.1196\/annals.1361.047"},{"key":"3","doi-asserted-by":"crossref","unstructured":"<i>Bohan, A., Peter, J. B.:<\/i> Polymyositis and dermatomyositis. N. Engl. J. Med., 1975, <i>292<\/i>(7), 344\u2013347.","DOI":"10.1056\/NEJM197502132920706"},{"key":"4","doi-asserted-by":"crossref","unstructured":"<i>Gunawardena, H., Betteridge, Z. E., McHugh, N. J.:<\/i> Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford), 2009, <i>48<\/i>(6), 607\u2013612.","DOI":"10.1093\/rheumatology\/kep078"},{"key":"5","doi-asserted-by":"crossref","unstructured":"<i>Targoff, I. N.:<\/i> Myositis specific autoantibodies. Curr. Rheumatol. Rep., 2006, <i>8<\/i>(3), 196\u2013203.","DOI":"10.1007\/s11926-996-0025-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"<i>Buchbinder, R., Forbes, A., Hall, S., et al.:<\/i> Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann. Intern. Med., 2001, <i>134<\/i>(12), 1087\u20131095.","DOI":"10.7326\/0003-4819-134-12-200106190-00008"},{"key":"7","doi-asserted-by":"crossref","unstructured":"<i>Buchbinder, R., Hill, C. L.:<\/i> Malignancy in patients with inflammatory myopathy. Curr. Rheumatol. Rep., 2002, <i>4<\/i>(5), 415\u2013426.","DOI":"10.1007\/s11926-002-0087-9"},{"key":"8","unstructured":"<i>Andr\u00e1s, C., Ponyi, A., Constantin, T., et al.:<\/i> Myositis associated with tumors. [Myositisek tumorral t\u00f6rt\u00e9n\u0151 t\u00e1rsul\u00e1sa.] Magy. Onkol., 2002, <i>46<\/i>(3), 253\u2013259. [Hungarian]"},{"key":"9","doi-asserted-by":"crossref","unstructured":"<i>Sigurgeirsson, B., Lindel\u00f6f, B., Edhag, O., et al.:<\/i> Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med., 1992, <i>326<\/i>(6), 363\u2013367.","DOI":"10.1056\/NEJM199202063260602"},{"key":"10","doi-asserted-by":"crossref","unstructured":"<i>Wakata, N., Kurihara, T., Saito, E., et al.:<\/i> Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int. J. Dermatol., 2002, <i>41<\/i>(11), 729\u2013734.","DOI":"10.1046\/j.1365-4362.2002.01648.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"<i>Azuma, K., Yamada, H., Ohkubo, M., et al.:<\/i> Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod. Rheumatol., 2011, <i>21<\/i>(2), 178\u2013183.","DOI":"10.3109\/s10165-010-0362-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"<i>Marie, I.:<\/i> Morbidity and mortality in adult polymyositis and dermatomyositis. Curr. Rheumatol. Rep., 2012, <i>14<\/i>(3), 275\u2013285.","DOI":"10.1007\/s11926-012-0249-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"<i>Hill, C. L., Zhang, Y., Sigurgeirsson, B., et al.:<\/i> Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet, 2001, <i>357<\/i>(9250), 96\u2013100.","DOI":"10.1016\/S0140-6736(00)03540-6"},{"key":"14","unstructured":"<i>Rovensky, J., Tuchynova, A.:<\/i> Polymyalgia rheumatica, temporal arteritis and occurence of malignant tumors. In: Schoenfeld, Y., Gershwin, M. E. (eds.): Cancer and Autoimmunity. Elsevier, Amsterdam, 2000."},{"key":"15","doi-asserted-by":"crossref","unstructured":"<i>Chen, Y. J., Wu, C. Y., Shen, J. L.:<\/i> Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br. J. Dermatol., 2001, <i>144<\/i>(4), 825\u2013831.","DOI":"10.1046\/j.1365-2133.2001.04140.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"<i>Bielsa, I.:<\/i> New autoantibodies in dermatomyositis. Actas Dermosifiliogr., 2009, <i>100<\/i>(3), 182\u2013189.","DOI":"10.1016\/S1578-2190(09)70043-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"<i>Chinoy, H., Fertig, N., Oddis, C. V., et al.:<\/i> The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann. Rheum. Dis., 2007, <i>66<\/i>(10), 1345\u20131349.","DOI":"10.1136\/ard.2006.068502"},{"key":"18","doi-asserted-by":"crossref","unstructured":"<i>Kaji, K., Fujimoto, M., Hasegawa, M., et al.:<\/i> Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford), 2007, <i>46<\/i>(1), 25\u201328.","DOI":"10.1093\/rheumatology\/kel161"},{"key":"19","doi-asserted-by":"crossref","unstructured":"<i>Targoff, I. N., Mamyrova, G., Trieu, E. P., et al.:<\/i> A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum., 2006, <i>54<\/i>(11), 3682\u20133689.","DOI":"10.1002\/art.22164"},{"key":"20","doi-asserted-by":"crossref","unstructured":"<i>Ohashi, M., Shu, E., Tokuzumi, M., et al.:<\/i> Anti-p155\/140 antibody-positive dermatomyositis with metastasis originating from an unknown site. Acta Derm. Venereol., 2011, <i>91<\/i>(1), 84\u201385.","DOI":"10.2340\/00015555-0955"},{"key":"21","doi-asserted-by":"crossref","unstructured":"<i>Dank\u00f3, K., Ponyi, A., Molnar, A. P., et al.:<\/i> Paraneoplastic myopathy. Curr. Opin. Rheumatol., 2009, <i>21<\/i>(6), 594\u2013598.","DOI":"10.1097\/BOR.0b013e3283317fa5"}],"container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/OH.2014.29984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T09:56:03Z","timestamp":1590141363000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/doi\/10.1556\/oh.2014.29984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":21,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1556\/OH.2014.29984"],"URL":"https:\/\/doi.org\/10.1556\/oh.2014.29984","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}